Issue 145

Cybin to acquire Small Pharma, creating largest DMT programme

Cybin Inc. has confirmed it will acquire Small Pharma, combining to create the psychedelic industry’s largest and most advanced deuterated DMT programme. UK-based Small Pharma is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions.

The company has developed short-duration psychedelic therapies for mental health conditions, raising $63 million in capital since 2021. It has also released the first placebo-controlled efficacy results for DMT in the treatment of Major Depressive Disorder (MDD), progressing two clinical-stage DMT-based programmes, a pipeline of preclinical assets, and an IP portfolio.

READ MORE

UK GOVERNMENT ISSUES RAPID RESPONSE ON PSYCHEDELIC RESEARCH

The Parliamentary Office of Science and Technology has issued an announcement to elucidate the topic for policymakers.

Read More

ONE-THIRD OF THOSE UNDER 50 OPEN TO PSYCHEDELIC MEDICINE

The survey’s findings are further evidence of the growing acceptance of psychedelic treatment options.

Read More

BUSINESS AND INVESTMENT

GH Research reports Q2 financial results. The company has US$238.1 million in cash and cash equivalents, with a Phase II 5-MeO-DMT trial underway.

atai announces Phase I trial results of ibogaine for opioid use disorder. No serious adverse events were reported.

Psychedelic-assisted therapy sparks debate among patients and researchers. Some say the benefits of psychedelic medicines need to be better understood.

Ethical and clinical dilemmas posed by psychedelic-assisted therapy. The need to protect patients is of paramount importance.

Psychedelic Press to publish final journal. The UK-based publication was launched in 2008.

Indigenous communities seek to preserve traditions associated with entheogens. Advocates believe they should play a central role in the psychedelic medicine industry.

Psilocybin services in Oregon. A patient shares their experiences of the recently created programme.

SCIENCE AND RESEARCH

Potential analgesic effects of psychedelic medicines on chronic pain conditions. Except for in sciatica, better pain relief was reported compared to conventional medication in all examined conditions.

The markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy. The study sought to understand the underlying mechanisms of psilocybin therapy.

MDMA appears to reduce challenging psychedelic experiences. It has been accredited with reducing feelings of discomfort and melancholia.

REGULATION AND LEGISLATION

Colorado to host public sessions to devise laws for psychedelic medicine. Five sessions have been scheduled to guide regulatory reform.

Presidential candidate Robert F. Kennedy Jr. supports access to psychedelic medicine. He has previously pushed for widespread changes on drug policy.

A committee in Hawaii meets to discuss the regulation of psychedelic medicine. The task force was recently established under the governor’s office.

ARTICLES OF INTEREST

A quarter of 16-year-old girls in England seeking mental healthcare. This is twice the proportion accessing care four years ago.

UK chancellor to target mental illness at work. £53 billion is currently spent on sickness and disability benefits.

Cigarettes and mental illness. Smoking increases the risk of being hospitalised for a mental illness by 250%.

Partner with us